New Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026

PRESS RELEASE New Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026 Presentations ...

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific ...

The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website ( beginning on April 18. 1 AACR Annual ...
CURE

Real-World ADC Data Support Use in More Diverse Patients

Real-world data show ADCs benefit more diverse, older and pretreated patients, helping guide care and build confidence beyond ...
Fierce Biotech

Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline

Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...
BioPharma Dive

Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and ...